Skip to content
Tech News
← Back to articles

AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion

2026-07-14 | original
read original more articles

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment.

Explore topics: agreement agreement china astrazeneca astrazeneca entered cancer
Related:
Sam Neill has died
Reed Jobs would rather talk about curing cancer than his last name
Apple commits $30 billion to Broadcom for U.S. chipmaking push
Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens GSK Partnership
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

© 2026 GoKawiil

About | Editorial Policy | Contact